Home › Research › Tau biomarkers
Cognitive Stability Among Plasma p-tau 181 Negative Individuals: A 5-year Analysis of the Multidomain Alzheimer Prevention Trial Study
Bellelli F, Barreto PS, Cantet C, Ousset PJ, Blennow K, Vellas B, Angioni D, MAPT/DSA Study Group.. The journals of gerontology. Series A, Biological sciences and medical sciences, 2025-06-01
Topic: Amyloid, tau and blood-test diagnosis
Background This study aims to assess the evolution of cognitive performances over a 5-year follow-up period in community-dwelling older people with negative plasma p-tau181 levels and to determine whether frailty could discriminate between those who experience cognitive decline and those who do not, in the p-tau negative groups. Methods This is a 5-year analysis of the Multidomain Alzheimer Prevention Trial (MAPT) testing cognitive evolution among 503 community-dwelling individuals with available data on plasma p-tau181. Negative p-tau status was assigned according to 3 different cut-offs: amyloid-PET positivity (9.6 pg/mL), highest tertile for baseline p-tau181 distribution (10.9 pg/mL), and Alzheimer's disease diagnosis prediction (12.4 pg/mL) cut-offs.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bellelli, F., Barreto, P. S., Cantet, C., Ousset, P. J., Blennow, K., Vellas, B., et al. (2025). Cognitive Stability Among Plasma p-tau 181 Negative Individuals: A 5-year Analysis of the Multidomain Alzheimer Prevention Trial Study. The journals of gerontology. Series A, Biological sciences and medical sciences. https://doi.org/10.1093/gerona/glaf113
Vancouver
Bellelli F, Barreto PS, Cantet C, Ousset PJ, Blennow K, Vellas B, et al. Cognitive Stability Among Plasma p-tau 181 Negative Individuals: A 5-year Analysis of the Multidomain Alzheimer Prevention Trial Study. The journals of gerontology. Series A, Biological sciences and medical sciences. 2025. doi:10.1093/gerona/glaf113. PMID: 40383731.
BibTeX
@article{bellelli2025-40383731,
author = {Bellelli, F. and Barreto, P. S. and Cantet, C. and Ousset, P. J. and Blennow, K. and Vellas, B. and Angioni, D. and {MAPT/DSA Study Group}},
title = {{Cognitive Stability Among Plasma p-tau 181 Negative Individuals: A 5-year Analysis of the Multidomain Alzheimer Prevention Trial Study}},
journal = {The journals of gerontology. Series A, Biological sciences and medical sciences},
year = {2025},
doi = {10.1093/gerona/glaf113},
pmid = {40383731},
url = {https://doi.org/10.1093/gerona/glaf113}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Methods This is a 5-year analysis of the Multidomain Alzheimer Prevention Trial (MAPT) testing cognitive evolution among 503 community-dwelling individuals with available data on plasma p-tau181.
- Negative p-tau status was assigned according to 3 different cut-offs: amyloid-PET positivity (9.6 pg/mL), highest tertile for baseline p-tau181 distribution (10.9 pg/mL), and Alzheimer's disease diagnosis prediction (12.4 pg/mL) cut-offs.
- Cognition was measured using a validated composite cognitive score derived from the Z-scores of 4 cognitive tests.
- Longitudinal changes from baseline in the composite cognitive score according to plasma p-tau181 status were compared using linear mixed models.
Why it matters
This 5-year analysis of the MAPT trial assessed cognitive change in community-dwelling older people with negative plasma p-tau181 and whether frailty distinguished those who declined. It describes the course of people without the biomarker and does not test a treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 47/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 45 of the 96 points we could judge it on, which is 47 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journals of gerontology. Series A, Biological sciences and medical sciences) |
| Journal's citation record | 3 / 4 | The Journals of Gerontology Series A: journal h-index 274 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40383731) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 45 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 96 points we could judge it on is 47 out of 100. |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Tau biomarkers
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.